Influenza and COVID-19
Fall has yet to arrive, but already we hear warnings of a combined viral outbreak of influenza and COVID, despite...
Co-opting Price Transparency
Originally designed to empower patients, price transparency has transformed into a legal liability, becoming a documentation burden for healthcare institutions.
Why Scientists Lie
There is a fine line between a lie and trying to simplify complex scientific topics. A subtle difference that forms...
Of Approvals and Mandates
A COVID-19 vaccine received full FDA approval, prompting calls for vaccine mandates. But when patients act as consumers, regulatory approval...
Data & Individuals
Healthcare is immersed in data, which now define all aspects of clinical care. But data do not define the individual,...
Science, Politics & Ethics of Boosters
We recently approved booster shots for the COVID-19 vaccine, raising many issues across different fronts, all defined by one core...
Does COVID-19 Mutate Rapidly?
The pandemic lingers on, defined by the viral variants of COVID-19. We explore the mutation patterns to determine whether the...
Physician Advocacy Rings Hollow
Physician leaders call for advocacy, galvanizing the medical community to take up public health issues. But these calls appear hollow,...
Are Politicians Beholden to ‘Do No Harm’?
Political rhetoric on public health policy is now affecting individual patient decisions. Should politicians be held liable for the clinical...
Empowering Police Clinically
Law enforcement often makes rapid decisions in high pressure situations - not unlike physicians. Perhaps law enforcement should train more...
The Healthcare Jungle
Corporate medicine has changed the once autonomous physician profession into a traditional labor workforce, eliminating the art of medicine.
Trumpism, Post-Pandemic
Individualism has long defined America, but over the country's history, it has appeared differently - the current version being both...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more